These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 29311084)
21. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections. Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127 [TBL] [Abstract][Full Text] [Related]
22. Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres. Shields RK; Yücel E; Turzhitsky V; Merchant S; Min JS; Watanabe AH J Glob Antimicrob Resist; 2024 Jun; 37():190-194. PubMed ID: 38588973 [TBL] [Abstract][Full Text] [Related]
32. [Clinical pharmacokinetics of an imipenem-cilastatin combination]. Singlas E Presse Med; 1990 Apr; 19(13):598-605. PubMed ID: 2139939 [TBL] [Abstract][Full Text] [Related]
33. Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. Pietroski NA; Graziani AL; Lawson LA; Bland JA; Rogers JD; MacGregor RR Antimicrob Agents Chemother; 1991 May; 35(5):972-5. PubMed ID: 1854179 [TBL] [Abstract][Full Text] [Related]
34. The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease. Rolando N; Wade JJ; Philpott-Howard JN; Casewell MW; Williams R J Antimicrob Chemother; 1994 Jan; 33(1):163-7. PubMed ID: 8157557 [No Abstract] [Full Text] [Related]
35. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Nichols WW; Mouton JW Antimicrob Agents Chemother; 2015 Apr; 59(4):2299-304. PubMed ID: 25645843 [TBL] [Abstract][Full Text] [Related]
36. [Imipenem-cilastatin-relebactam used to treat ventilator-associated pneumonia developing after infection with SARS-CoV-2]. Zahornacký O; Porubčin Š; Rovňáková A; Jarčuška P Klin Mikrobiol Infekc Lek; 2022 Mar; 28(1):18-21. PubMed ID: 36183413 [TBL] [Abstract][Full Text] [Related]
37. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889 [TBL] [Abstract][Full Text] [Related]
38. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program. Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628 [TBL] [Abstract][Full Text] [Related]
39. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. Chan CY; Lai KN; Lam AW; Li PK; Chung WW; French GL J Antimicrob Chemother; 1991 Feb; 27(2):225-32. PubMed ID: 2055813 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]